Capabilities by Industry: Healthcare

Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector.  Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe, Australia and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.

In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.

Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals; and biotechnology. 

Below we highlight a few of the transactions on which we have advised in this area:

Recent Transactions

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

30-Nov-18
$NA
United States flag
Target: 

Aisthesis

United States flag
Acquiror: 
NAPA Management Services Corporation

Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities

15-Sep-20
$NA
United States flag
Target: 

Surgery Partners’ Anesthesia Services

United States flag
Acquiror: 
NorthStar Anesthesia

Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia   

01-Dec-15
$NA
United Kingdom flag
Target: 

Allied Healthcare

Germany flag
Acquiror: 
AURELIUS Investments

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

07-Mar-16
$NA
Germany flag
Target: 

Boehringer Ingelheim

United States flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

24-Nov-16
$NA
Israel flag
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

19-Dec-18
$NA
United States flag
Target: 

Pfizer Inc. Consumer Health Business

United Kingdom flag
Acquiror: 
GlaxoSmithKline plc

Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture

19-Apr-16
$NA
United States flag
Target: 

Total Care Medicaid Plan

United States flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

04-Oct-20
Undisclosed
France flag
Target: 

Cosmetic applications endolysin

Netherlands flag
Acquiror: 
L’Oréal

Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100

28-Dec-22
Pending
Undisclosed
Japan flag
Target: 

Eisai Distribution Co., Ltd.

Japan flag
Acquiror: 
Yasuda Logistics Corporation

Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

19-Dec-18
$NA
Australia flag
Target: 

Starpharma Holdings Limited, patented VivaGel BV® product

Italy, USA flags
Acquiror: 
ITF Pharma, US subsidiary of Italfarmaco S.p.A.

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

09-Feb-21
Undisclosed
United States flag
Target: 

US Acute Care Solutions

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson

23-Feb-10
$NA
United States flag
Target: 

Heartscape Technologies, Inc.

United States flag
Acquiror: 
Roper Industries, Inc.

Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company

18-Dec-13
$NA
United States flag
Target: 

Fidelis SeniorCare Inc. (Michigan Heath Plan)

United States flag
Acquiror: 
Centene Corporation

Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

05-Feb-14
$NA
Sweden flag
Target: 

Unfors Raysafe AB

United States flag
Acquiror: 
Fluke Biomedical Corporation

Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products

15-Jan-20
$NA
United States flag
Target: 

OurHealth

United States flag
Acquiror: 
General Atlantic

Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health

12-Jul-10
$NA
United States flag
Target: 

Breast Care Business of Ethicon-Endo Surgery

United States flag
Acquiror: 
Devicor Medical Products, Inc. (a GTCR portfolio company)

Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery

30-Nov-17
$NA
Germany flag
Target: 

MorphoSys AG

China flag
Acquiror: 
I-Mab

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

20-Feb-20
$NA
United Kingdom flag
Target: 

Asia and US rights to Physiogel

Korea flag
Acquiror: 
LG Household & Health Care

Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

Pages

show all